Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

A naturally occurring sugar, 2-deoxy-D-ribose, may promote hair growth by forming new blood vessels. There is skepticism about its effectiveness and concerns about potential side effects, with some users comparing it to existing treatments like Minoxidil and finasteride.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

A user shared their positive experience with a hair transplant at Wimpole Clinic, performed by Dr. Malkani, and discussed using finasteride at a reduced dose due to side effects. They also mentioned avoiding minoxidil due to heart pain and taking supplements like biotin, marine collagen, viviscal, and krill oil.

The conversation is about using vitamin C and Magnesium L-Threonate for hair growth by reducing DHT binding to dermal papilla cells. The original post about vitamin C's pH levels and sebum control was possibly removed by a moderator.

A 22-year-old male has been using oral minoxidil, oral finasteride, microneedling, and ketoconazole for hair loss treatment over two years, experiencing some regrowth and maintenance. He reports side effects from finasteride, including erectile dysfunction, and slight libido impact from minoxidil.

Minoxidil's effectiveness varies due to genetic differences in the SULT1A1 enzyme, affecting how well it converts to its active form, minoxidil sulfate. Hyper-responders may experience rapid hair growth and increased side effects, such as pericardial effusion, even at low doses.

The conversation discusses the tension theory as a cause of male pattern baldness (MPB), suggesting that scalp tension and reduced subcutaneous fat layer contribute to hair loss. Treatments mentioned include Minoxidil, finasteride, microneedling, scalp massages, and Botox.

The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The user experienced increased hair density after starting 1mg finasteride in February and 2.5mg oral minoxidil two months ago, along with 10mg biotin daily. They initially used topical minoxidil but switched to oral due to application difficulties and have seen improvements without significant side effects.

A user is experiencing worsening hair loss despite using 2.5mg Dutasteride, RU58841, and Minoxidil daily for over 8 months. They are concerned that daily nicotine from vaping might be counteracting the treatments.

User discusses potential hair loss cure involving growth factors from a hairy mole. Dr. Wrassman responds, saying clinical trials may happen in 2022.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

A 20-year-old with thinning hair has low vitamin D and normal testosterone. They are prescribed oral minoxidil and vitamin D, and are questioning if finasteride is also necessary.

A user shared their positive experience with hair regrowth after six months of using minoxidil and finasteride, reporting no side effects. They showed progress photos and expressed hope for full restoration of their hair.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. User feedback suggests 2-deoxy-D-ribose is ineffective.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.

The post and conversation discuss Verteporfin's potential as a hair loss treatment. It's shown promise in regrowing hair after transplants and might be effective with microneedling.

Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.

A 32-year-old is seeing new hair growth after two months of using minoxidil foam twice daily, finasteride every other day, and weekly microneedling. They previously had a hair transplant but did not use medication afterward, which they now regret.

The user has been using minoxidil 5% and finasteride 0.1% topically, along with oral minoxidil and finasteride, for three months without major improvement in hair loss. They are also taking vitamin D3, B12, iron, and zinc supplements.

The user reported progress in hair loss treatment using oral finasteride, keto 2% shampoo, and vitamin D. They experienced reduced hair fall, fewer scalp issues, and hope for improved hair density.